Adrenergic mechanisms and the adenyl cyclase system in atopic dermatitis
- PMID: 9456
- DOI: 10.1111/1523-1747.ep12514494
Adrenergic mechanisms and the adenyl cyclase system in atopic dermatitis
Abstract
Patients with atopic dermatitis have abnormal autonomic responses of the arterioles, pilomotor smooth muscle, and sweat glands. Their lesions have been reported to contain increased amounts of the neurohumors, acetylcholine and norepinephrine, as well as increased activity of acetylcholinesterase and catechol-O-methyltransferase. In vitro studies of epidermis show that beta adrenergic agonists fail to evoke the normal inhibition of mitosis of basal cells of patients with atopic dermatitis. Epidermis removed not only from the lesions, but also from normal-appearing skin, responded abnormally. The increase in intracellular levels of cAMP after exposure to catecholamines was similar in normal and atopic epidermis. Lymphocytes and PMN leukocytes isolated from patients with atopic dermatitis show both a decreased physiologic response (glycogenolysis and inhibition of lysosome enzyme release) and a decreased rise in intracellular levels of cAMP upon incubation with beta agonists, but a normal response to PGE1. Cortisol increases the response of lymphocyte adenyl cyclase to both agonists and, in the case of the patients with atopic disease, more than overcomes the depressed response to beta agonists. Because the leukocytes respond normally to PGE1 and because others have reported normal activities of skin and adenyl cyclase, phosphodiesterase, and protein kinases, we conclude that the step responsible for the diminished beta adrenergic response lies antecedent to the catalytic site of adenyl cyclase.
Similar articles
-
Pharmacophysiology of atopic dermatitis.Clin Rev Allergy. 1986 Feb;4(1):43-65. doi: 10.1007/BF02991187. Clin Rev Allergy. 1986. PMID: 3008974 Review.
-
Intracellular 3',5'-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis.J Invest Dermatol. 2001 Jan;116(1):3-11. doi: 10.1046/j.1523-1747.2001.01196.x. J Invest Dermatol. 2001. PMID: 11168792
-
Adrenoceptor function in atopic dermatitis: in vitro and in vivo observations.Acta Derm Venereol Suppl (Stockh). 1985;114:93-7. doi: 10.2340/000155551149397. Acta Derm Venereol Suppl (Stockh). 1985. PMID: 2860767
-
The effects of catecholamine and related compounds on the adenyl cyclase system in the epidermis.Br J Dermatol. 1975 Jul;93(1):29-36. doi: 10.1111/j.1365-2133.1975.tb06472.x. Br J Dermatol. 1975. PMID: 1191526
-
Basic and clinical aspects of atopic dermatitis.Ann Allergy. 1984 Jun;52(6):386-95. Ann Allergy. 1984. PMID: 6145376 Review.
Cited by
-
β-Adrenergic Receptor Trafficking, Degradation, and Cell Surface Expression Are Altered in Dermal Fibroblasts from Hypertrophic Scars.J Invest Dermatol. 2018 Jul;138(7):1645-1655. doi: 10.1016/j.jid.2018.01.037. Epub 2018 Feb 22. J Invest Dermatol. 2018. PMID: 29476776 Free PMC article. Clinical Trial.
-
Immune mechanisms in atopic dermatitis.Springer Semin Immunopathol. 1981;4(3):275-91. doi: 10.1007/BF01892182. Springer Semin Immunopathol. 1981. PMID: 7041302 Review. No abstract available.
-
Beta adrenergic receptors in keratinocytes.Dermatol Clin. 2007 Oct;25(4):643-53, x. doi: 10.1016/j.det.2007.06.012. Dermatol Clin. 2007. PMID: 17903623 Free PMC article. Review.
-
Pharmacophysiology of atopic dermatitis.Clin Rev Allergy. 1986 Feb;4(1):43-65. doi: 10.1007/BF02991187. Clin Rev Allergy. 1986. PMID: 3008974 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources